Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,402
Employees1,402
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,402
Employees1,402

IONS Key Statistics

Market cap
8.99B
Market cap8.99B
Price-Earnings ratio
-25.87
Price-Earnings ratio-25.87
Dividend yield
Dividend yield
Average volume
5.84M
Average volume5.84M
High today
$54.98
High today$54.98
Low today
$53.76
Low today$53.76
Open price
$54.10
Open price$54.10
Volume
2.57M
Volume2.57M
52 Week high
$86.74
52 Week high$86.74
52 Week low
$40.03
52 Week low$40.03

Stock Snapshot

With a market cap of 8.99B, Ionis Pharmaceuticals(IONS) trades at $54.98. The stock has a price-to-earnings ratio of -25.87.

On 2026-07-19, Ionis Pharmaceuticals(IONS) stock moved within a range of $53.76 to $54.98. With shares now at $54.98, the stock is trading +2.3% above its intraday low and 0.0% below the session's peak.

Trading volume for Ionis Pharmaceuticals(IONS) stock has reached 2.57M, versus its average volume of 5.84M.

Over the past 52 weeks, Ionis Pharmaceuticals(IONS) stock has traded between a high of $86.74 and a low of $40.03.

Over the past 52 weeks, Ionis Pharmaceuticals(IONS) stock has traded between a high of $86.74 and a low of $40.03.

IONS News

Nasdaq 20h
Cathie Wood Just Bet Big on This Biotech Stock

Key Points The biotech has a strong pipeline and is growing its revenue. In June, the FDA approved Ionis's drug, Tryngolza, to treat severe hypertriglyceridem...

Cathie Wood Just Bet Big on This Biotech Stock
Simply Wall St 1d
Ionis Begins First ION337 Trial In Dravet Syndrome Patients

Ionis Pharmaceuticals (NasdaqGS:IONS) has dosed the first participant in the Phase 1-2 ASCEND trial of ION337 for Dravet syndrome. The study marks the first cl...

Ionis Begins First ION337 Trial In Dravet Syndrome Patients
TipRanks 4d
Wolfe cuts Ionis Pharma to Peer Perform after disappointing trial data

Wolfe Research downgraded Ionis Pharmaceuticals (IONS) to Peer Perform from Outperform. Two trial disappointments – TTR and tau – nullified most of the firm’s p...

Analyst ratings

88%

of 24 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

More IONS News

TipRanks 4d
Ionis Pharmaceuticals downgraded to Peer Perform from Outperform at Wolfe Research

Wolfe Research downgraded Ionis Pharmaceuticals (IONS) to Peer Perform from Outperform. Published first on TheFly – the ultimate source for real-time, market-m...

Seeking Alpha 5d
Biogen drops after additional mid-stage trial data for Ionis-partnered Alzheimer’s drug

Biogen (CIIB) shares fell in the morning hours on Tuesday after the company announced additional data from a mid-stage trial for diranersen, a novel experimenta...

Biogen drops after additional mid-stage trial data for Ionis-partnered Alzheimer’s drug
TipRanks 5d
Ionis says Biogen presents Phase 2 CELIA data at AAIC

Ionis Pharmaceuticals (IONS) announced that its partner, Biogen (BIIB), shared data from the Phase 2 CELIA study evaluating diranersen, an investigational antis...

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.